Company profiles describe technology and scientific approach. LONGEFI does not value companies, rate them as investments or score them here — company profiles are reference material, not intelligence output.
Private
Cellular reprogramming
Research-first company pursuing partial epigenetic reprogramming to restore cell health and function. Heavily funded, deliberately pre-clinical, and publishing in the open literature rather than racing to a single asset.
BEAMPublic
Base editing
Precision genetic medicine company using base editing to make single-letter DNA changes without double-strand breaks.
BIOAPublic
Human-longevity-data-derived metabolic aging therapeutics
Clinical-stage company that builds drug programmes from human longevity cohort data, targeting metabolic and inflammatory pathways of aging with an emphasis on preserving muscle during weight loss.
BIIBPublic
Antisense oligonucleotide (ASO)
Neuroscience company developing diranersen (BIIB080 / IONIS-MAPTRx), an antisense oligonucleotide designed to target MAPT mRNA and reduce tau production, evaluated in the Phase 2 CELIA study in early Alzheimer's disease.
Private
iPSC-derived cell therapy
Engineered cell therapies derived from induced pluripotent stem cells, with a lead Parkinson's programme.
Private
Fundamental aging biology, integrated stress response
Alphabet-backed research company studying the biology of aging and translating that work into therapeutics, including the eIF2B activator fosigotifator for integrated-stress-response-driven disease.
Private
Portfolio model across aging pathways
Holding company building a portfolio of programmes against established aging pathways, including AMPK activation, mTORC1-selective inhibition, TG2 inhibition and AMH/AMHR2 biology.
CDXCPublic
Nicotinamide riboside (consumer NAD+)
Consumer-facing NAD+ precursor business with an associated clinical research programme.
Private
CRISPR screening for rejuvenation factors
Uses genome-wide CRISPR screens in stem cells to discover factors that control cellular rejuvenation, aiming to convert screen hits into therapeutics.
Private
Immune-mediated senescent cell clearance
Develops small molecules that recruit the innate immune system to clear senescent cells rather than killing them directly.
DNLIPublic
Oligonucleotide Transport Vehicle (OTV), blood-brain barrier delivery
Neurodegeneration company applying its Oligonucleotide Transport Vehicle to cross the blood-brain barrier; DNL628 (OTV:MAPT) is designed to reduce tau through MAPT targeting in Alzheimer's disease.
ENLVPublic
Allogeneic macrophage-reprogramming cell therapy
Clinical-stage company developing Allocetra, an allogeneic cell therapy intended to reprogram macrophages toward immune homeostasis. Company-reported development includes an FDA Regenerative Medicine Advanced Therapy designation in knee osteoarthritis.
GENFPublic
SIRT6 gene therapy (AAV)
London-listed gene therapy company developing AAV-delivered SIRT6 programmes aimed at age-related disease, built around the centenarian-associated SIRT6 variant.
Private
AI target discovery, organism-state modeling
Applies physics-informed machine learning to longitudinal health data to model the organism as a dynamical system and identify intervention targets for aging and age-related disease.
Private
Immune secretome therapy
Develops an immune-modulating secretome intended to counter age-related muscle and immune decline.
3696.HKPublic
Generative AI drug discovery
Generative chemistry and target discovery company with clinical assets originating from its AI platform.
NTLAPublic
In vivo CRISPR gene editing
Clinical-stage genome editing company with in vivo CRISPR programmes in amyloidosis and hereditary angioedema.
IONSPublic
Antisense oligonucleotide (ASO)
RNA-targeted medicines company whose antisense platform discovered diranersen (IONIS-MAPTRx / BIIB080), a MAPT-directed antisense oligonucleotide for Alzheimer's disease; Biogen exercised its licence option and holds a worldwide exclusive royalty-bearing licence to develop and commercialise it.
Private
siRNA transcriptional reset
Develops siRNA therapeutics designed to reset dysregulated transcriptional networks in aged cells back toward a youthful state, using its RESET discovery platform.
Private
Partial epigenetic reprogramming (OSK)
Advancing partial reprogramming toward the clinic with an initial focus on optic neuropathy.
LCTXPublic
Allogeneic cell transplant therapies from pluripotent lines
Clinical-stage company manufacturing allogeneic cell transplants intended to replace cells lost to age-related degeneration, led by a retinal pigment epithelium programme in dry age-related macular degeneration.
Private
Canine longevity therapeutics
Veterinary medicine company developing the first drugs intended to extend healthy lifespan in dogs, led by LOY-002 for senior dogs.
Private
NAD+ precursors
Developing pharmaceutical-grade NAD+ precursors intended to be tested as drugs rather than supplements.
Private
Mitochondrial augmentation (cell therapy)
Cell therapy company whose Mitochondrial Augmentation Technology enriches a patient's own hematopoietic stem cells with healthy mitochondria; lead programme MNV-201 is in development for myelodysplastic syndrome and mitochondrial disease.
Private
Mitochondrial transplantation
Develops transplantation of lab-grown, autologous mitochondria as a therapy for age-related mitochondrial dysfunction.
Private
Epigenetic reprogramming, mRNA delivery
Epigenetic reprogramming company using machine learning to discover transcription-factor combinations delivered by mRNA, aiming to restore youthful cell function without losing cell identity.
RXRXPublic
Phenomics + ML drug discovery
Industrial-scale cellular imaging paired with machine learning to map biology and generate candidates.
Private
AAV gene therapy, partial reprogramming
Gene therapy company developing AAV-delivered programmes, including FGF21-based constructs and partial-reprogramming approaches, against drivers of age-related disease.
Private
Cellular reprogramming, autophagy
Focused company targeting ten additional years of healthy human lifespan through reprogramming, plasma-inspired interventions and autophagy restoration.
Private
Selective senolytic prodrugs
Uses a chemistry platform to design prodrugs activated inside senescent cells, aiming for tissue-selective clearance.
Private
Computational reprogramming discovery
Uses virtual cell models to search for reprogramming factor sets that rejuvenate cells without erasing identity.
Private
mTOR inhibition / immune aging
Developing selective TORC1 inhibitors intended to improve immune function in older adults.
Private
Mitophagy-inducing small molecules
Swiss biotech developing small molecules that induce mitophagy — the selective clearance of damaged mitochondria — led by VNA-318 for CNS and muscle disorders.
Private
Partial reprogramming (Yamanaka factors), AAV delivery
Gene therapy company developing partial-reprogramming therapeutics based on Yamanaka-factor expression, led by YB002 for Alzheimer's disease.
